Nicotinic receptor modulation: Advantages for successful Alzheimer's disease therapy

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 203-216

  Geerts, H ^a,c   Finkel, L ^b   Carr, R ^b   Spiros, A ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b In Silico BioSciences   (United States)

^c Silico Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NICOTINIC RECEPTOR; RIVASTIGMINE; NOOTROPIC AGENT;

ACTION POTENTIAL; ALLOSTERISM; ALZHEIMER DISEASE; CHOLINERGIC SYNAPSE; CHOLINERGIC TRANSMISSION; COMPUTER MODEL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR INTRINSIC ACTIVITY; AGED; METABOLISM; REVIEW;

AGED; ALZHEIMER DISEASE; GALANTAMINE; HUMANS; NOOTROPIC AGENTS; RECEPTORS, NICOTINIC;

EID: 0036044104     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_19     Document Type: Conference Paper

References (33)

1. Alkondon M, Pereira EF, Cortes WS, Maelicke. A, Albuquerque EX (1997) Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9: 2734-2742
2. Anglister L, Stiles JR, Salpeter MM (1994) Acetylcholinesterase density and turnover number at frog neuromuscular junctions, with modeling of their role in synaptic function. Neuron 12: 783-794
3. Auerbach A, Akk G (1998) Desensitization of mouse nicotinic acetylcholine receptor channels. A two-gate mechanism. J Gen Physiol 112: 181-197
4. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163: 495-529
5. Blesa R (2000) Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 11[Suppl 1]: 28-34
6. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99: 459-496
7. Buisson B, Gopalakrishnan M, Arneric SP, Sullivan JP, Bertrand D (1996) Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J Neurosci 16: 7880-7891
8. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49: 175-184
9. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet ii: 1403
10. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401-1406
11. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-4133
12. Elhamdani A, Palfrey HC, Artalejo CR (2001) Quantal size is dependent on stimulation frequency and calcium entry in calf chromaffin cells. Neuron 31: 819-830
13. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001) Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21: 7993-8003
14. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276: 13541-13546
15. Kuffler SW, Yoshikami D (1975) The number of transmitter molecules in a quantum: an estimate from iontophoretic application of acetylcholine at the neuromuscular synapse. J Physiol 251: 465-482
16. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48: 391-395
17. Lilienfeld S, Parys W (2000) Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 11[Suppl 1]: 19-27
18. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour D J, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401
19. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49: 279-288
20. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK (1999) Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73: 1635-1640
21. Nordberg A, Nilsson-Hakansson L, Adem A, Hardy J, Alafuzoff I, Lai Z, Herrera-Marschitz M, Winblad B (1989) The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 79: 353-362
22. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(-) 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9: 21-27
23. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22: 609-613
24. Papke RL, Meyer E, Nutter T, Uteshev VV (2000) α 7 receptor-selective agonists and modes of α 7 receptor activation. Eur J Pharmacol 393: 179-195
25. Pereira EF, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, Albuquerque EX (1994) Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270: 768-778
26. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34: 247-265
27. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54: 2261-2268
28. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A (2000) Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Stand [Suppl] 176: 68-73
29. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49: 1-6
30. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269-2276
31. Thomsen T, Kewitz H (1990) Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46: 1553-1558
32. Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J (2000) The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 55: 1278-1283
33. Wilcock GK, Lilienfeld S, Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321: 1445-1449